Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

PubWeight™: 3.85‹?› | Rank: Top 1%

🔗 View Article (PMID 11677200)

Published in Gastroenterology on November 01, 2001

Authors

W J Sandborn1, S B Hanauer, S Katz, M Safdi, D G Wolf, R D Baerg, W J Tremaine, T Johnson, N N Diehl, A R Zinsmeister

Author Affiliations

1: The Mayo Clinic, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu

Articles citing this

(truncated to the top 100)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21

TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85

Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82

Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med (2013) 1.71

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol (2009) 1.67

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65

Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther (2006) 1.58

Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53

Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44

Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36

New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21

Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J (2007) 1.19

Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis (2003) 1.14

Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ (2003) 1.13

Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol (2010) 1.10

Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09

Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol (2006) 1.06

Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis (2004) 1.03

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J (2013) 1.02

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology (2001) 1.01

T cell apoptosis and inflammatory bowel disease. Gut (2004) 1.00

Gastrointestinal Behçet's disease: a review. World J Gastroenterol (2015) 1.00

Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99

Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int (2007) 0.98

Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis (2012) 0.97

Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96

Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest (2009) 0.95

Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93

Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci (2008) 0.92

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence (2013) 0.92

Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm (2014) 0.92

Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91

Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91

Crohn's disease as an immunodeficiency. Expert Rev Clin Immunol (2010) 0.89

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm (2015) 0.89

Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3. Clin Exp Immunol (2009) 0.88

A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS One (2012) 0.88

Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss. J Bone Miner Res (2014) 0.88

Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. J Inflamm (Lond) (2008) 0.88

Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Langenbecks Arch Surg (2011) 0.87

Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease. PLoS One (2009) 0.85

Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.85

Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol (2009) 0.84

Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84

Management of cutaneous disorders related to inflammatory bowel disease. Ann Gastroenterol (2012) 0.84

A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci (2004) 0.84

Expanding the armamentarium for the spondyloarthropathies. Arthritis Res Ther (2004) 0.83

Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis (2004) 0.83

Management of inflammatory bowel disease. Postgrad Med J (2004) 0.83

Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. Int J Inflam (2012) 0.82

Refractory lymphocytic enterocolitis and tumor necrosis factor antagonist therapy. Clin Gastroenterol Hepatol (2009) 0.82

If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. J Exp Med (2007) 0.82

The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol (2012) 0.81

Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol (2014) 0.81

Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.81

Adalimumab in Crohn's disease. Biologics (2007) 0.80

Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int (2014) 0.80

Tumor necrosis factor receptor 1 functions as a tumor suppressor. Am J Physiol Gastrointest Liver Physiol (2011) 0.80

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol (2009) 0.80

Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology (2016) 0.80

Autophagy Contributes to the Induction of Anti-TNF Induced Macrophages. J Crohns Colitis (2015) 0.79

Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol (2010) 0.79

Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79

Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis (2014) 0.79

Clinically silent Crohn's disease in a patient with Takayasu's arteritis unresponsive to conventional therapies. Rheumatol Int (2012) 0.79

Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair. Gastroenterology (2016) 0.79

Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle) (2012) 0.78

A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther (2017) 0.78

Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J (2014) 0.78

Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by granulocyte-/granulocyte-macrophage colony stimulating factors. Mol Pain (2013) 0.78

Crohn's disease unmasked following etanercept treatment for ankylosing spondylitis. BMJ Case Rep (2013) 0.77

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci (2012) 0.77

Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2004) 0.77

Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications. Z Rheumatol (2013) 0.77

Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis (2015) 0.77

Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord (2015) 0.77

Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis. Rheumatol Int (2012) 0.77

Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association? Clin Rheumatol (2011) 0.77

[Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement]. Z Rheumatol (2008) 0.76

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA. Dig Dis Sci (2016) 0.76

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis (2015) 0.76

Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol (2014) 0.76

Microbiota, intestinal immunity, and mouse bustle. Acta Naturae (2014) 0.76

In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia. Br J Haematol (2014) 0.76

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol (2016) 0.76

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol (2016) 0.76

Disseminated tuberculosis infection and paradoxical reaction during antimycobacterial treatment related to TNF-alpha blocker agent Infliximab. Respir Med Case Rep (2014) 0.75

An unusual case of granulomatous lung disease. A clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS J (2006) 0.75

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. J Inflamm Res (2009) 0.75

Crohn's disease: not all anti-TNFs are the same! Inflamm Bowel Dis (2002) 0.75

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med (2017) 0.75

In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut (2007) 0.75

Current issues in pediatric inflammatory bowel disease-associated arthropathies. World J Gastroenterol (2014) 0.75

Articles by these authors

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24

Progress in development of the index of ADL. Gerontologist (1970) 15.21

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67

A measure of primary sociobiological functions. Int J Health Serv (1976) 8.93

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73

Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet (1998) 7.70

Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26

Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A (1994) 6.96

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90

Active life expectancy. N Engl J Med (1983) 6.36

Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24

Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc (1983) 6.17

Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med (1991) 6.16

A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med (1998) 5.67

Designing the national resident assessment instrument for nursing homes. Gerontologist (1990) 5.49

Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology (1992) 4.84

Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut (1990) 4.60

Simplified assessment of segmental colonic transit. Gastroenterology (1987) 4.59

Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology (1998) 4.52

12. Index of ADL. Med Care (1976) 4.27

Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology (1993) 4.23

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21

Surgical management of Meckel's diverticulum. An epidemiologic, population-based study. Ann Surg (1994) 4.16

A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02

Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 3.90

Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand (2003) 3.79

Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology (1990) 3.77

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60

A prospective study of functional status among community elders. Am J Public Health (1984) 3.51

The evolution of mutation rates: separating causes from consequences. Bioessays (2000) 3.48

A patient questionnaire to identify bowel disease. Ann Intern Med (1989) 3.43

Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc (1990) 3.34

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1997) 3.29

Chronic-disease classification in evaluation of medical care programs. Med Care (1969) 3.23

Risk of functional decline among well elders. J Clin Epidemiol (1989) 3.17

A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14

Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12

Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology (1993) 2.99

Hereditary angioedema: a broad review for clinicians. Arch Intern Med (2001) 2.92

Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol (2000) 2.89

Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88

Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86

The hierarchical relationship between activities of daily living and instrumental activities of daily living. J Chronic Dis (1987) 2.81

Medical costs in community subjects with irritable bowel syndrome. Gastroenterology (1995) 2.81

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78

Risk factors associated with symptoms of gastroesophageal reflux. Am J Med (1999) 2.75

Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62

Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther (2002) 2.59

Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol (1993) 2.57

Vertical strabismus after cataract surgery. Ophthalmology (1996) 2.56

Temporal lobe seizures: lateralization with MR volume measurements of the hippocampal formation. Radiology (1990) 2.56

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55

Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39

Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst (1991) 2.35

Sex differences in evaluation and outcome of unstable angina. JAMA (2000) 2.33

Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32

A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol (2000) 2.27

Activation of Pak by membrane localization mediated by an SH3 domain from the adaptor protein Nck. Curr Biol (1997) 2.24

Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc (1994) 2.23

Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med (1982) 2.23

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21

Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology (1992) 2.17

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 2.15

Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci (1996) 2.15

Anticipation in Crohn's disease may be influenced by gender and ethnicity of the transmitting parent. Am J Gastroenterol (1998) 2.14

Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2015) 2.13

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12

Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology (1994) 2.12

Quantitation of epidermal nerves in diabetic neuropathy. Neurology (1996) 2.12

Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil (2014) 2.11

Relation among personality and symptoms in nonulcer dyspepsia and the irritable bowel syndrome. Gastroenterology (1990) 2.09

Severe exercise-induced ischemia does not identify high risk patients with normal left ventricular function and one- or two-vessel coronary artery disease. J Am Coll Cardiol (1994) 2.08

Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther (2014) 2.08

Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer (1973) 2.05

Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03

Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol (1996) 2.01

Self-reported abuse and gastrointestinal disease in outpatients: association with irritable bowel-type symptoms. Am J Gastroenterol (1995) 1.99

Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain (2000) 1.97

Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol (1995) 1.94

Predictors of outcome after percutaneous endoscopic gastrostomy: a community-based study. Mayo Clin Proc (1992) 1.94

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation (1998) 1.93

Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92

Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain (1999) 1.90

Effects and costs of day-care services for the chronically ill: a randomized experiment. Med Care (1980) 1.90

Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol (1999) 1.90

The ras recruitment system, a novel approach to the study of protein-protein interactions. Curr Biol (1998) 1.90

Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am J Gastroenterol (1998) 1.88

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.85

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84